We

prepared the condensed consolidated financial statements following the

requirements of the Securities and Exchange Commission (SEC) for interim

reporting. As permitted under those rules, certain footnotes or other financial

information that are normally required by accounting principles generally

accepted in the United States of America (U.S. GAAP) can be condensed or

omitted. Balance sheet amounts and operating results for subsidiaries operating

outside the U.S. are as of and for the three-month periods ended February 22,

2009, and February 24, 2008.

We made

certain reclassifications to prior-period amounts to conform to the

first-quarter 2009 presentation related to the presentation of noncontrolling

interests as a result of adopting a new accounting standard (See Note 2. Adoption of New Accounting

Policies.)

Revenues,

expenses, assets and liabilities can vary during each quarter of the year.

Therefore, the results and trends in these interim financial statements may not

be representative of those for the full year.

We are

responsible for the unaudited financial statements included in this

document. The financial statements include all normal and recurring

adjustments that are considered necessary for the fair presentation of our

financial position and operating results.

The

information included in this Quarterly Report on Form 10-Q should be read in

conjunction with the consolidated financial statements and accompanying notes

included in Pfizer s Annual Report on Form 10-K for the year ended December

31, 2008.

On January

26, 2009, we announced that we entered into a definitive merger agreement under

which we will acquire Wyeth in a cash-and-stock transaction valued on that date

at $50.19 per share, or a total of $68 billion. While we have taken actions and

incurred costs associated with the pending transaction that are reflected in our

financial statements, the pending acquisition of Wyeth will not be reflected in

our financial statements until consummation. (See Note 14. Pending Acquisition of

Wyeth.)

Note 2. Adoption of New

Accounting Policies

As of

January 1, 2009, we adopted Financial Accounting Standards Board (FASB)

Statement of Financial Accounting Standards (SFAS) No. 141R, Business Combinations, as

amended. SFAS 141R, as amended, retains the purchase method of accounting for

acquisitions, but requires a number of changes, including changes in the way

assets and liabilities are recognized in purchase accounting. It also changes

the recognition of assets acquired and liabilities assumed arising from

contingencies, requires the capitalization of in-process research and

development costs at fair value and requires the expensing of

acquisition-related costs as incurred. The adoption of SFAS 141R, as amended,

did not impact our consolidated financial statements upon adoption, but does

impact the accounting for future acquisitions, including our pending acquisition

of Wyeth.

As of

January 1, 2009, we adopted FASB Financial Staff Position (FSP) SFAS No. 142-3,

Determination of the Useful

Life of Intangible Assets. FSP SFAS 142-3 amends the factors considered

in developing renewal or extension assumptions used to determine the useful life

of a recognized intangible asset. Among other things, in the absence of

historical experience, an entity will be required to consider assumptions used

by market participants. The adoption of FSP SFAS 142-3 did not impact our

consolidated financial statements upon adoption, but could impact the accounting

for future acquisitions.

As of

January 1, 2009, we adopted the provisions of FASB SFAS No. 157, Fair Value Measurements, as

amended, that we did not adopt as of January 1, 2008. SFAS 157, as amended,

defines fair value, expands related disclosure requirements and specifies a

hierarchy of valuation techniques based on the nature of the inputs used to

develop the fair value measures. The adoption of the remaining provisions of

SFAS 157, as amended, did not have a significant impact on our consolidated

financial statements upon adoption, but will impact the accounting for future

acquisitions, including our pending acquisition of Wyeth, and other events and

transactions measured at fair value.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

As of

January 1, 2009, we adopted FASB SFAS No. 160, Noncontrolling Interests in

Consolidated Financial Statements, an amendment of Accounting Research

Bulletin No. 51, Consolidated

Financial Statements. SFAS 160 provides guidance for the accounting,

reporting and disclosure of noncontrolling interests, previously referred to as

minority interests. A noncontrolling interest represents the portion of equity

(net assets) in a subsidiary not attributable, directly or indirectly, to a

parent. The adoption of SFAS 160 resulted in a number of changes to the

presentation of our consolidated financial statements, but the amounts

associated with noncontrolling interests are not significant. SFAS 160 could

impact our accounting for future acquisitions where we do not acquire 100% of

the entity and our accounting for the deconsolidations of

subsidiaries.

As of

January 1, 2009, we adopted Emerging Issues Task Force (EITF) Issue No. 07-1,

Accounting for Collaborative

Arrangements. EITF 07-1 provides guidance on: determining whether an

arrangement constitutes a collaborative arrangement within the scope of the

Issue; how costs incurred and revenue generated on sales to third parties should

be reported in the income statement; how an entity should characterize payments

on the income statement; and what participants should disclose in the notes to

the financial statements about a collaborative arrangement. The adoption of EITF

07-1 did not have a significant impact on our consolidated financial statements,

and additional disclosures have been provided. (See Note 4. Collaborative

Arrangements.)

As of

January 1, 2009, we adopted EITF Issue No. 08-3, Accounting by Lessees for

Maintenance Deposits. EITF 08-3 provides guidance that maintenance

deposits paid by a lessee and subsequently refunded only if a lessee fulfills a

maintenance obligation will be accounted for as a deposit asset. The adoption of

EITF 08-3 did not have a significant impact on our consolidated financial

statements.

As of

January 1, 2009, we adopted EITF Issue No. 08-6, Equity Method Investment Accounting

Considerations. EITF 08-6 clarifies how to account for certain

transactions involving equity method investments in areas such as how to

determine the initial carrying value of the investment; how to allocate the

difference between the investor s carrying value and the investor s share of the

underlying equity of the investment; how to perform an impairment assessment of

underlying intangibles held by the investee; how to account for the investee s

issuance of additional shares; and how to account for an investment on the cost

method when it had been previously accounted for under the equity method. The

adoption of EITF 08-6 did not have a significant impact on our consolidated

financial statements, but could impact the accounting for future equity method

investments.

As of

January 1, 2009, we adopted EITF Issue No. 08-7, Accounting for Defensive Intangible

Assets. EITF 08-7 clarifies the accounting for certain separately

identifiable assets, which an acquirer does not intend to actively use but

intends to hold to prevent its competitors from obtaining access to them. EITF

08-7 requires an acquirer to account for a defensive intangible asset as a

separate unit of accounting, which should be amortized to expense over the

period the asset diminishes in value. The adoption of EITF 08-7 did not have a

significant impact on our consolidated financial statements, but could impact

the accounting for future acquisitions.

Note 3.

Acquisitions

In the

first quarter of 2008, we acquired CovX, a privately held biotherapeutics

company specializing in preclinical oncology and metabolic research and the

developer of a biotherapeutics technology platform that we expect will enhance

our biologic portfolio. Also in the first quarter of 2008, we acquired all the

outstanding shares of Coley Pharmaceutical Group, Inc., (Coley), a

biopharmaceutical company specializing in vaccines and drug candidates designed

to fight certain cancers, allergy and asthma disorders, and autoimmune diseases,

for approximately $230 million. In connection with these and two smaller

acquisitions related to Animal Health, we recorded approximately $398 million in

Acquisition-related in-process

research and development charges.

Note 4. Collaborative

Arrangements

In the

normal course of business, we enter into collaborative arrangements with respect

to in-line medicines as well as medicines in development that require completion

of research and regulatory approval. Collaborative arrangements are contractual

agreements with third parties that involve a joint operating activity, typically

a research and/or commercialization effort, where both we and our partner are

active participants in the activity and are exposed to the significant risks and

rewards of the activity. Our rights and obligations under each

collaborative arrangement can vary. For example, we have agreements to

co-promote pharmaceutical products discovered by other companies, and we have

agreements where we partner to co-develop and/or participate together in

commercializing, marketing, promoting, manufacturing, or distributing a drug

product.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Payments

to or from our collaboration partners are presented in the statement of income

based on the nature of the arrangement (including its contractual terms), the

nature of the payments and applicable accounting guidance. Under co-promotion

agreements, we record the amounts received from our partners as alliance

revenues, a component of Revenues, when our

co-promotion partners are the principal in the transaction and we receive a

share in their net sales or profits. Alliance revenues are recorded when our

co-promotion partners ship the related product and title passes to their

customer. Expenses for selling and marketing these products are included in

Selling, informational and

administrative expenses. In arrangements where we manufacture product for

our partner, we record revenues when our partner sells the product and title

passes to their customer. All royalty payments to collaboration partners are

recorded as part of Cost of

sales.

The

amounts and classifications of payments (income/(expense)) between us and our

collaboration partners follow:

(millions

of dollars)

First

Quarter

Mar.

29,

2009

Mar.

30,

2008

Revenues

Revenues(a)

132

100

Revenues

Alliance revenues (b)

582

488

Total

Revenues

714

588

Cost

of sales (c)

(56

(31

Selling,

informational and administrative expenses

(17

(7

Research

and development expenses(d)

(194

(50

(a)

Represents

sales to our partners of products manufactured by

us.

(b)

Substantially

all related to amounts earned from our partners under co-promotion

agreements.

(c)

Primarily

related to royalties earned by our partners and cost of sales associated

with inventory purchased from our

partners.

(d)

Primarily

related to net reimbursements earned by our partners except that the first

quarter of 2009 also includes a $150 million milestone payment to one of

our partners.

The

amounts disclosed in the above table do not include transactions with third

parties other than our collaboration partners, or other costs associated with

the products under the collaboration arrangements.

Note 5. Cost-Reduction

Initiatives

We

incurred the following costs in connection with all of our cost-reduction

initiatives which began in 2005:

First

Quarter

(millions

of dollars)

Mar.

29,

2009

Mar.

30,

2008

Implementation

costs(a)

174

357

Restructuring

charges(b)

157

178

Total

costs related to our cost-reduction initiatives

331

535

(a)

For

the first quarter of 2009, included in Cost of sales ($76

million), Selling,

informational and administrative expenses ($46 million), Research and development

expenses ($41 million), and Other (income)/deductions

net ($11 million). For the first quarter of 2008, included in Cost of sales ($138 million), Selling, informational and

administrative expenses ($75 million), Research and development

expenses ($146 million), and Other

(income)/deductions-net ($2 million income).

(b)

Included

in Restructuring charges

and acquisition-related

costs.

From the

beginning of the cost-reduction initiatives in 2005 through March 29, 2009, the

restructuring charges primarily relate to our supply network transformation

efforts and the restructuring of our worldwide marketing and research and

development operations, and the implementation costs primarily relate to

depreciation arising from the shortening of the useful lives of certain assets,

as well as system and process standardization and the expansion of shared

services.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The

components of restructuring charges associated with all of our cost-reduction

initiatives follow:

(millions

of dollars)

Costs

Incurred

Through

Mar.

29,

2009

Activity

Through

Mar.

29,

2009(a)

Accrual

as

of

Mar.

29,

2009(b)

Employee

termination costs

5,285

3,500

1,785

Asset

impairments

1,311

1,311

Other

444

412

32

Total

restructuring charges

7,040

5,223

1,817

(a)

Includes

adjustments for foreign currency translation.

(b)

Included in Other current liabilities

($1.240 billion) and Other noncurrent liabilities

($577

million).

During the

first quarter of 2009, we expensed $135 million for Employee termination costs,

$18 million for Asset

impairments and $4 million for Other. Through March 29,

2009, Employee termination

costs represent the expected reduction of the workforce by approximately

31,000 employees, mainly in manufacturing, sales and research; and approximately

21,400 of these employees have been terminated. Employee termination costs

are recorded when the actions are probable and estimable and include accrued

severance benefits, pension and postretirement benefits. Asset impairments primarily

include charges to write down property, plant and equipment. Other primarily includes

costs to exit certain activities.

Note 6. Acquisition-Related

Costs

We

incurred the following acquisition-related costs in connection with our pending

acquisition of Wyeth:

First

Quarter

(millions

of dollars)

Mar. 29,

2009

Transaction

costs (a)

369

Pre-integration

costs and other(b)

28

Total

acquisition-related costs(c)

397

(a)

Transaction

costs include banking, legal, accounting and other costs directly related

to our pending acquisition of Wyeth. Substantially all of the costs

incurred to date are fees related to our $22.5 billion bridge term loan

credit agreement entered into with financial institutions on March 12,

2009 (see Note 8C.

Financial Instruments: Long-Term Debt) to partially fund our pending

acquisition of Wyeth. Upon our issuance of $13.5 billion of senior

unsecured notes on March 24, 2009, the commitment under the bridge term

loan credit agreement was reduced by an amount equal to the net proceeds

we received from such issuance, to a current balance of $9.1 billion, and,

accordingly, we expensed the portion of the bridge term loan credit

agreement fees associated with the $13.5 billion

reduction.

(b)

Pre-integration

costs represent external, incremental costs directly related to our

pending acquisition of Wyeth and include costs associated with preparing

for systems and other integration

activities.

(c)

Included

in Restructuring charges

and acquisition-related

costs.

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Comprehensive

Income/(Loss)

The

components of comprehensive income/(loss) follow:

First

Quarter

(millions

of dollars)

Mar.

29,

2009

Mar.

30,

2008

Net

income before allocation to noncontrolling interests

2,730

2,790

Other

comprehensive loss:

Currency translation adjustment

and other

(384

(575

Net unrealized gains/(losses) on

derivative financial instruments

(23

Net unrealized gains/(losses) on

available-for-sale securities

145

(14

Benefit plan

adjustments

159

84

Total other comprehensive

loss

(103

(504

Total

comprehensive income before allocation to noncontrolling

interests

2,627

2,286

Less: Comprehensive income

attributable to noncontrolling interests

Comprehensive

income attributable to Pfizer Inc.

2,625

2,278

Note 8. Financial

Instruments

A. Investments in Debt and

Equity Securities

Investments

in debt securities reflect the investment of proceeds on March 24, 2009, when

Pfizer issued $13.5 billion of senior unsecured notes in anticipation of the

acquisition of Wyeth (see Note

8C. Financial Instruments: Long-Term Debt). The note proceeds were generally

invested in short-term available-for-sale investments such as money market

funds, U.S. Treasury notes, and to a lesser extent, corporate debt.

B. Short-Term

Borrowings

Short-term

borrowings include amounts for commercial paper of $6.1 billion as of March 29,

2009.

As of

March 29, 2009, we had access to $8.2 billion of lines of credit, of which $6.0

billion expire within one year. Of these lines of credit, $8.1 billion are

unused, of which our lenders have committed to loan us $7.1 billion at our

request. $7.0 billion of the unused lines of credit, of which $5.0 billion

expire in the first quarter of 2010 and $2.0 billion expire in 2013, may be used

to support our commercial paper borrowings. The $5.0 billion of lines of credit

expiring in the first quarter of 2010 are subject to substantially the same

credit covenants as the bridge term loan credit agreement noted below. (See

Note 8G. Financial

Instruments: Credit Covenants.)

On March

12, 2009, we entered into a $22.5 billion bridge term loan credit agreement

(bridge credit agreement) in connection with the

pending acquisition of Wyeth. Upon our issuance of $13.5 billion of senior

unsecured notes in March 2009 (see Note 8C. Financial Instruments:

Long-Term Debt), the commitment under

the bridge credit agreement was reduced by an amount equal to the net proceeds

we received from such issuance, to a current balance of $9.1 billion. As of

March 29, 2009, no amounts have been drawn down under the bridge credit

agreement, and borrowings under the bridge credit agreement can only occur on

the consummation date of the Wyeth transaction. Amounts drawn under the bridge

credit agreement must be used to fund a portion of the Wyeth merger

consideration and certain fees and expenses incurred in connection with the

merger and would mature 364 days after the merger consummation date but may be

extended under certain conditions. The loan interest rate is to be calculated at

the highest of specified common base rates, plus specified fixed-rates. The

bridge credit agreement will terminate upon the earliest to occur of the

following: (i) the consummation of merger, (ii) December 31, 2009, (iii) the

abandonment of the merger, (iv) the termination of the merger agreement or (v)

the date on which the commitments under the bridge credit agreement are

cancelled in full. The pending acquisition of Wyeth is expected to occur at the

end of the third quarter or during the fourth quarter of 2009.

Certain

bridge credit agreement fees have been expensed as Acquisition-related costs in

the income statement caption Restructuring charges and

acquisition-related costs (see Note 6.

Acquisition-related costs), while

other bridge credit agreement fees have been deferred and are included in Other assets, deferred taxes and

deferred charges.

10

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The bridge

credit agreement subjects us to certain covenants until the commitment expires

and all loans under the agreement, if any, have been paid. (See Note 8G. Financial Instruments:

Credit Covenants.)

C. Long-Term

Debt

On March

24, 2009, as part of our financing of the pending acquisition of Wyeth, we

issued $13.5 billion of senior unsecured notes. Information as of March 29, 2009

is as follows:

(millions

of dollars)

Maturity

Date

2009

Senior

unsecured notes:

Floating rate notes at the

three-month London Interbank

Offering

Rate (LIBOR), plus 1.95%

March

2011

1,250

4.45%(a)

March

2012

3,500

5.35%(a)

March

2015

3,000

6.20%(a)

March

2019

3,250

7.20%(a)

March

2039

2,500

Total

long-term debt issued in connection with the pending acquisition of

Wyeth

13,500

(a)

The

fixed-rate debt is callable at any time at the greater of 100% of the

principal amount or the sum of the present

values of principal and interest discounted at the U.S. Treasury rate,

plus

0.50%.

D. Derivative Financial

Instruments and Hedging Activities

Foreign Exchange Risk - A

significant portion of our revenues, earnings and net investments in foreign

affiliates is exposed to changes in foreign exchange rates. We seek to manage

our foreign exchange risk in part through operational means, including managing

expected same-currency revenues in relation to same-currency costs and

same-currency assets in relation to same-currency liabilities. Depending on

market conditions, foreign exchange risk is also managed through the use of

derivative financial instruments and foreign currency debt. These financial

instruments serve to protect net income and net investments against the impact

of the translation into U.S. dollars of certain foreign-exchange-denominated

transactions. The aggregate notional amount of foreign exchange derivative

financial instruments hedging or offsetting foreign currency exposures is $35

billion. The derivative financial instruments primarily hedge or offset

exposures in euro, Japanese yen, and Swedish kroner.

All

derivative contracts used to manage foreign currency risk are measured at fair

value and are reported as assets or liabilities on the consolidated balance

sheet. Changes in fair value are reported in earnings or deferred, depending on

the nature and purpose of the financial instrument (offset or hedge

relationship) and the effectiveness of the hedge relationships, as

follows:

We

defer on the balance sheet the effective portion of the gains or losses on

foreign currency forward-exchange contracts and foreign currency swaps

that are designated as cash flow hedges and reclassify those amounts, as

appropriate, into earnings in the same

period or periods during which the hedged transaction affects

earnings.

We

recognize the gains and losses on forward-exchange contracts and foreign

currency swaps that are used to offset the same foreign currency assets or

liabilities immediately into earnings along with the earnings impact of

the items they generally offset. These contracts essentially take the

opposite currency position of that reflected in the month-end balance

sheet to counterbalance the effect of any currency

movement.

We

recognize the gains and losses impact on foreign currency swaps designated

as hedges of our net investments in earnings in three ways:

over time for the periodic net swap payments; immediately to the extent of

any change in the difference between the foreign exchange spot rate and

forward rate; and upon sale or substantial liquidation of our net

investments to the extent of change in the foreign exchange spot

rates.

We defer

on the balance sheet foreign exchange gains and losses related to foreign

exchange-denominated debt designated as a hedge of our net investments and

reclassify those amounts into earnings upon the sale or substantial liquidation

of our net investments.

Any

ineffectiveness is recognized immediately into earnings. There was no

significant ineffectiveness in the first quarter of 2009 or the first quarter of

2008.

11

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Interest Rate Risk - Our

interest-bearing investments, loans and borrowings are subject to interest rate

risk. We invest and loan primarily on a short-term or variable-rate basis;

however, due to the pending acquisition of Wyeth and in light of current market

conditions, we currently borrow primarily on a long-term, fixed-rate basis. From

time to time, depending on market conditions, we will fix interest rates either

through entering into fixed-rate investments or through the use of derivative

financial instruments. The aggregate notional amount of interest rate derivative

financial instruments is $4 billion. The derivative financial instruments

primarily offset euro fixed-rate debt, and to a lesser extent, hedge U.S.

fixed-rate debt.

All

derivative contracts used to manage interest rate risk are measured at fair

value and reported as assets or liabilities on the consolidated balance sheet.

Changes in fair value are reported in earnings, as follows:

We

recognize the gains and losses on interest rate swaps that are designated

as fair value hedges in earnings upon the

recognition of the change in fair value of the hedged risk. We recognize

the offsetting earnings impact of fixed-rate debt attributable to the

hedged risk also in earnings.

Any

ineffectiveness is recognized immediately into earnings. There was no

significant ineffectiveness in the first quarter of 2009 or the first quarter of

2008.

Information

about the fair values of our derivative financial instruments and debt

designated as hedging instruments and the impact on our consolidated balance

sheet follows:

March

29, 2009

Assets

Liabilities

(millions

of dollars)

Balance

Sheet

Location(a)

Fair

Value(b)

Balance

Sheet

Location(a)

Fair

Value (b)

Derivative

financial instruments designated as hedging instruments:

Interest

rate swaps

OCA

OCL

Interest

rate swaps

ONCA

314

ONCL

Foreign

currency swaps

OCA

17

OCL

Foreign

currency swaps

ONCA

143

ONCL

30

Foreign

currency forward-exchange contracts

OCA

276

OCL

266

Total

derivative financial instruments designated as hedging

instruments:

751

311

Derivative

financial instruments not designated as hedging

instruments:

Foreign

currency swaps

ONCA

ONCL

139

Foreign

currency forward-exchange contracts

OCA

233

OCL

650

Total

derivative financial instruments not designated as hedging

instruments

233

789

Total

derivative financial instruments

984

1,100

Nonderivative

financial instruments designated as hedging instruments:

Foreign

currency short-term borrowings

STB

1,273

Foreign

currency long-term debt

LTD

1,927

Total

nonderivative financial instruments designated as hedging

instruments

3,200

(a)

The

primary consolidated balance sheet caption indicates the financial

statement classification of the amount associated with the financial

instrument used to hedge or offset risk. The abbreviations used are

defined as follows: OCA = Taxes and other current

assets; ONCA = Other assets, deferred taxes

and deferred charges; OCL = Other current

liabilities; ONCL = Other noncurrent

liabilities; STB = Short-term

borrowings; and LTD = Long-term

debt.

(b)

See

Note 8E. Financial

Instruments: Fair Value for a description of the valuation

techniques used to determine fair

values.

12

PFIZER

INC. AND SUBSIDIARY COMPANIES

NOTES TO

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Certain of

our derivative instruments have credit-risk-related contingent features designed

to reduce our counterparties exposure to our risk of defaulting on amounts

owed. The aggregate fair value of these derivative instruments that are in a

liability

position is $315 million, for which we have posted collateral of $230 million in

the normal course of business. These features include the requirement to pay

additional collateral in the event of a debt-rating organization ratings

downgrade. If there had been a downgrade to an A rating, or its equivalent, on

March 29, 2009, we would have been required to post an additional $140 million

of collateral to our counterparties. If there had been a downgrade to below an A

rating, or its equivalent, on March 29, 2009, we would have been required to

post an additional $168 million of collateral to our counterparties. (See Note 8F: Financial Instruments:

Credit Risk.)

Information

about gains and losses on our derivative financial instruments and debt

designated as hedging instruments and the impact on our comprehensive income

follows:

First

Quarter 2009

(millions

of dollars)

Amount

of

Gains/(Losses)

Recognized in

Earnings(b)

Amount

of

Gains/(Losses)